{"id":"NCT01194830","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study","officialTitle":"A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2011-10","completion":"2011-10","firstPosted":"2010-09-03","resultsPosted":"2012-10-26","lastUpdate":"2014-01-29"},"enrollment":234,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Linagliptin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Linagliptin","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study","primaryOutcome":{"measure":"Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks","timeFrame":"baseline, 24 weeks","effectByArm":[{"arm":"Placebo Tablet","deltaMin":-0.25,"sd":0.16},{"arm":"Linagliptin 5 mg Tablet","deltaMin":-0.84,"sd":0.15}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0005"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":93,"countries":["United States"]},"refs":{"pmids":["25236917","23134211"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":120},"commonTop":["Hyperglycaemia","Urinary tract infection"]}}